Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries: 2-year follow-up of 33 cases

Saberi, Hooshang; Firouzi, Masoumeh; Habibi, Zohreh; Moshayedi, Pouria; Aghayan, Hamid Reza; Arjmand, Babak; Hosseini, Kazem; Razavi, Hassan Emami; Yekaninejad, Mir Saeed

doi:10.3171/2011.6.spine10917

Cited by 112 publications

(80 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous preclinical studies using various SCI models across several species have not indicated safety concerns regarding SCs. Furthermore, several clinical Brought to you by | Carleton University OCUL Authenticated Download Date | 6/27/15 4:10 AM studies suggest their safety and feasibility for the treatment of human SCI (Saberi et al, 2008(Saberi et al, , 2011Zhou et al, 2012). Therefore, transplantation of SCs has significant therapeutic potential for the clinical treatment of persons with SCI.…”

Section: Prospectusmentioning

confidence: 96%

“…In the USA, a trial testing the safety of transplantation of autologous human SCs is underway in The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine (www.clinicaltrials.govNCT01739023) (Guest et al, 2013). In addition, Saberi et al (2011) reported autologous SC transplantation in Iran for 33 patients with chronic thoracic SCI and demonstrated its safety and partial recovery of sensorimotor function with a 2-year follow-up, although the studies were not conducted under rigorous FDA oversight. Future approaches should involve strategies aimed at improving SC survival, blocking some of the multiple pathomechanisms in the lesion milieu, modifying the scar, promoting better axon regeneration, and utilizing new rehabilitation techniques following SCI.…”

Section: Prospectusmentioning

confidence: 97%

See 1 more Smart Citation

Schwann cell transplantation for spinal cord injury repair: its significant therapeutic potential and prospectus

Kanno¹,

Pearse²,

Ozawa

et al. 2015

Reviews in the Neurosciences

101

View full text Add to dashboard Cite

AbstractTransplantation of Schwann cells (SCs) is a promising therapeutic strategy for spinal cord repair. The introduction of SCs into the injured spinal cord has been shown to reduce tissue loss, promote axonal regeneration, and facilitate myelination of axons for improved sensorimotor function. The pathology of spinal cord injury (SCI) comprises multiple processes characterized by extensive cell death, development of a milieu inhibitory to growth, and glial scar formation, which together limits axonal regeneration. Many studies have suggested that significant functional recovery following SCI will not be possible with a single therapeutic strategy. The use of additional approaches with SC transplantation may be needed for successful axonal regeneration and sufficient functional recovery after SCI. An example of such a combination strategy with SC transplantation has been the complementary administration of neuroprotective agents/growth factors, which improves the effect of SCs after SCI. Suspension of SCs in bioactive matrices can also enhance transplanted SC survival and increase their capacity for supporting axonal regeneration in the injured spinal cord. Inhibition of glial scar formation produces a more permissive interface between the SC transplant and host spinal cord for axonal growth. Co-transplantation of SCs and other types of cells such as olfactory ensheathing cells, bone marrow mesenchymal stromal cells, and neural stem cells can be a more effective therapy than transplantation of SCs alone following SCI. This article reviews some of the evidence supporting the combination of SC transplantation with additional strategies for SCI repair and presents a prospectus for achieving better outcomes for persons with SCI.

show abstract

Section: Prospectusmentioning

confidence: 96%

Section: Prospectusmentioning

confidence: 97%

Schwann cell transplantation for spinal cord injury repair: its significant therapeutic potential and prospectus

Kanno¹,

Pearse²,

Ozawa

et al. 2015

Reviews in the Neurosciences

101

View full text Add to dashboard Cite

show abstract

“…A clinical trial of Schwann cells for SCI has been published that was completed in Iran. 17,18,22 As an autologous cell therapy, immune suppression may not be required (reducing risk), but each preparation represents an independent workload that must be uniquely characterized, in contrast to the use of allografted cell lines that may be derived from a cell bank.…”

Section: Initial Summary Of the Test Review Of Schwann Cellsmentioning

confidence: 98%

Optimization of the decision-making process for the selection of therapeutics to undergo clinical testing for spinal cord injury in the North American Clinical Trials Network

Guest

Aarabi

Grossman

et al. 2012

SPI

View full text Add to dashboard Cite

The North American Clinical Trials Network (NACTN) includes 9 clinical centers funded by the US Department of Defense and the Christopher Reeve Paralysis Foundation. Its purpose is to accelerate clinical testing of promising therapeutics in spinal cord injury (SCI) through the development of a robust interactive infrastructure. This structure includes key committees that serve to provide longitudinal guidance to the Network. These committees include the Executive, Data Management, and Neurological Outcome Assessments Committees, and the Therapeutic Selection Committee (TSC), which is the subject of this manuscript. The NACTN brings unique elements to the SCI field. The Network's stability is not restricted to a single clinical trial. Network members have diverse expertise and include experts in clinical care, clinical trial design and methodology, pharmacology, preclinical and clinical research, and advanced rehabilitation techniques. Frequent systematic communication is assigned a high value, as is democratic process, fairness and efficiency of decision making, and resource allocation. This article focuses on how decision making occurs within the TSC to rank alternative therapeutics according to 2 main variables: quality of the preclinical data set, and fit with the Network's aims and capabilities. This selection process is important because if the Network's resources are committed to a therapeutic, alternatives cannot be pursued. A proposed methodology includes a multicriteria decision analysis that uses a Multi-Attribute Global Inference of Quality matrix to quantify the process. To rank therapeutics, the TSC uses a series of consensus steps designed to reduce individual and group bias and limit subjectivity. Given the difficulties encountered by industry in completing clinical trials in SCI, stable collaborative not-for-profit consortia, such as the NACTN, may be essential to clinical progress in SCI. The evolution of the NACTN also offers substantial opportunity to refine decision making and group dynamics. Making the best possible decisions concerning therapeutics selection for trial testing is a cornerstone of the Network's function.

show abstract

“…In both studies, there were no significant changes in patients' MRI scans, and they reported neither neurological worsening nor improvement. They only reported autonomic functional recovery and improved quality of life 12,13 .…”

Section: Schwann Cellsmentioning

confidence: 99%

Current perspectives in stem cell therapy for spinal cord repair in humans: a review of work from the past 10 years

Mariano

Batista

Barbosa

et al. 2014

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Spinal cord injury (SCI) and amyotrophic laterals sclerosis (ALS) are devastating neurological conditions that affect individuals worldwide, significantly reducing quality of life, both for patients and their relatives. Objective: The present review aims to summarize the multiple restorative approaches being developed for spinal cord repair, the use of different stem cell types and the current knowledge regarding stem cell therapy. Method: Review of the literature from the past 10 years of human studies using stem cell transplantation as the main therapy, with or without adjuvant therapies. Conclusion: The current review offers an overview of the state of the art regarding spinal cord restoration, and serves as a starting point for future studies.Keywords: spinal cord injury, amyotrophic lateral sclerosis, stem cells, stem cell therapy. RESUMOLesão medular (LM) e esclerose lateral amiotrófica (ELA) são condições devastadoras que acometem pessoas em todo o mundo, reduzindo a qualidade de vida tanto de pacientes como de entes queridos. Objetivo: A atual revisão tem como alvo as múltiplas abordagens restauradoras para a regeneração medular, o uso de diferentes tipos celulares e o atual conhecimento a cerca da terapia com células tronco. Método: Revisão de literatura dos últimos 10 anos usando transplantes de células tronco como estratégia principal, com ou sem terapia adjuvante, em humanos. Conclusão: A presente revisão oferece uma visão geral acerca da restauração medular e serve de ponto de partida para estudos futuros.Palavras-chave: lesão medular, esclerose lateral amiotrófica, células tronco, terapia com células tronco.

show abstract

Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries: 2-year follow-up of 33 cases

Cited by 112 publications

References 110 publications

Schwann cell transplantation for spinal cord injury repair: its significant therapeutic potential and prospectus

Schwann cell transplantation for spinal cord injury repair: its significant therapeutic potential and prospectus

Optimization of the decision-making process for the selection of therapeutics to undergo clinical testing for spinal cord injury in the North American Clinical Trials Network

Current perspectives in stem cell therapy for spinal cord repair in humans: a review of work from the past 10 years

Contact Info

Product

Resources

About